Literature DB >> 11217426

Pathogenesis of Marek's disease virus infection.

B W Calnek1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11217426     DOI： 10.1007/978-3-642-56863-3_2

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN： 0070-217X            Impact factor:   4.291


× No keyword cloud information.
  86 in total

1.  The Herpesviridae Conserved Multifunctional Infected-Cell Protein 27 (ICP27) Is Important but Not Required for Replication and Oncogenicity of Marek's Disease Alphaherpesvirus.

Authors:  Nagendraprabhu Ponnuraj; Yung-Tien Tien; Widaliz Vega-Rodriguez; Andrea Krieter; Keith W Jarosinski
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

2.  The ORF012 gene of Marek's disease virus type 1 produces a spliced transcript and encodes a novel nuclear phosphoprotein essential for virus growth.

Authors:  Timo Schippers; Keith Jarosinski; Nikolaus Osterrieder
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

3.  Marek's disease virus-encoded Meq gene is involved in transformation of lymphocytes but is dispensable for replication.

Authors:  Blanca Lupiani; Lucy F Lee; Xiaoping Cui; Isabel Gimeno; Amy Anderson; Robin W Morgan; Robert F Silva; Richard L Witter; Hsing-Jien Kung; Sanjay M Reddy
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-02       Impact factor: 11.205

4.  Comparative sequence analysis of a highly oncogenic but horizontal spread-defective clone of Marek's disease virus.

Authors:  Stephen J Spatz; Yuguang Zhao; Lawrence Petherbridge; Lorraine P Smith; Susan J Baigent; Venugopal Nair
Journal:  Virus Genes       Date:  2007-08-25       Impact factor: 2.332

5.  Marek's disease virus phosphorylated polypeptide pp38 alters transcription rates of mitochondrial electron transport and oxidative phosphorylation genes.

Authors:  Michael S Piepenbrink; Xinhui Li; Priscilla H O'Connell; Karel A Schat
Journal:  Virus Genes       Date:  2009-05-27       Impact factor: 2.332

6.  Revaccination with Marek's disease vaccines induces productive infection and superior immunity.

Authors:  Changxin Wu; Junji Gan; Qiao Jin; Chuangfu Chen; Ping Liang; Yantao Wu; Xuefen Liu; Li Ma; Fred Davison
Journal:  Clin Vaccine Immunol       Date:  2008-12-03

7.  Attenuation of Marek's disease virus by deletion of open reading frame RLORF4 but not RLORF5a.

Authors:  Keith W Jarosinski; Nikolaus Osterrieder; Venugopal K Nair; Karel A Schat
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

8.  Marek's disease virus undergoes complete morphogenesis after reactivation in a T-lymphoblastoid cell line transformed by recombinant fluorescent marker virus.

Authors:  Caroline Denesvre; Sylvie Rémy; Laetitia Trapp-Fragnet; Lorraine P Smith; Sonia Georgeault; Jean-François Vautherot; Venugopal Nair
Journal:  J Gen Virol       Date:  2015-11-26       Impact factor: 3.891

9.  Viral control of vTR expression is critical for efficient formation and dissemination of lymphoma induced by Marek's disease virus (MDV).

Authors:  Najat Chbab; Annemarie Egerer; Inês Veiga; Keith W Jarosinski; Nikolaus Osterrieder
Journal:  Vet Res       Date:  2010-04-29       Impact factor: 3.683

10.  The Meq oncoprotein of Marek's disease virus interacts with p53 and inhibits its transcriptional and apoptotic activities.

Authors:  Xufang Deng; Xiangdong Li; Yang Shen; Yafeng Qiu; Zixue Shi; Donghua Shao; Yamei Jin; Hongjun Chen; Chan Ding; Li Li; Puyan Chen; Zhiyong Ma
Journal:  Virol J       Date:  2010-11-26       Impact factor: 4.099
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.